Evidence map›Paper›PMID 37403405›Full record

Trial reportJournal of the International AIDS Society2023

Patterns of PrEP continuation and coverage in the first year of use: a latent class analysis of a programmatic PrEP trial in Kenya.

Kenneth K Mugwanya, Adam Palayew, Torin Schaafsma, Elizabeth M Irungu, Elizabeth Bukusi, Nelly Mugo, Jennifer Morton, Josephine Odoyo, Kenneth Ngure, Jared M Baeten and 1 more

Open access · goldAbstract readClinical Trial
In one paragraph

Trial report in Journal of the International AIDS Society, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 13 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Lenacapavir for HIV Prevention in Africa: Opportunities, Barriers, and Policy Priorities.Journal of the International Association of Providers of AIDS Care
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Kenneth K MugwanyaDepartment of Epidemiology, University of Washington, Seattle, Washington, USA.ORCID 0000-0001-5208-7468
Adam PalayewDepartment of Epidemiology, University of Washington, Seattle, Washington, USA.ORCID 0000-0002-1904-5730
Torin SchaafsmaDepartment of Global Health, University of Washington, Seattle, Washington, USA.
Elizabeth M IrunguCentre for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya.ORCID 0000-0002-7401-3758
Elizabeth BukusiDepartment of Obstetrics and Gynecology, University of Washington, Seattle, Washington, USA.
Nelly MugoDepartment of Global Health, University of Washington, Seattle, Washington, USA.
Jennifer MortonDepartment of Global Health, University of Washington, Seattle, Washington, USA.
Josephine OdoyoCentre for Microbiology Research, Kenya Medical Research Institute, Nairobi, Kenya.
Kenneth NgureDepartment of Global Health, University of Washington, Seattle, Washington, USA.ORCID 0000-0002-8062-0933
Jared M BaetenDepartment of Global Health, University of Washington, Seattle, Washington, USA.ORCID 0000-0001-8242-8438
Partners Scale-Up Project
University of Washington · USKenya Medical Research Institute · KE

Funding

Optimizing Antiretroviral-Based HIV Prevention for HIV Serodiscordant CouplesR01MH095507 · NIMH · UNIVERSITY OF WASHINGTON · PI BAETEN, JARED · 2011 to 2020
$6.1M
PrEP adherence-concentration thresholds associated with HIV protection among African womenR01AI155086 · NIAID · UNIVERSITY OF WASHINGTON · PI ANDERSON, PETER L., MUGWANYA, KENNETH KIGGUNDU · 2021 to 2024
$3.1M
Integrating PrEP delivery in family planning clinics in KenyaR01MH123267 · NIMH · UNIVERSITY OF WASHINGTON · PI MUGWANYA, KENNETH KIGGUNDU · 2020 to 2024
$3.1M
A differentiated care model to improve the efficiency of PrEP delivery in KenyaR00MH118134 · NIMH · UNIVERSITY OF WASHINGTON · PI MUGWANYA, KENNETH KIGGUNDU · 2019 to 2021
$743k
NIAID NIH HHS R01 AI155086NIMH NIH HHS R00 MH118134NIMH NIH HHS R01 MH095507NIMH NIH HHS R01 MH123267
6 · The paper itself

Abstract

introductionEffective PrEP use is critical for impact, but data are limited on common patterns of continuation and coverage among persons using PrEP in real-world settings.

methodsData are from the Partners Scale-Up Project, a programmatic stepped-wedge cluster-randomized trial to integrate PrEP delivery in 25 Kenyan public health facilities conducted between February 2017 and December 2021. We evaluated PrEP continuation using visit attendance and pharmacy refill records, and computed medication possession ratio to define coverage during the first year of use. Latent class mixture models were used to identify and characterize membership to different PrEP continuation patterns. Multinomial logistic regression was used to examine the association between group trajectories and demographic and behaviour characteristics.

resultsOverall, 4898 persons initiated PrEP, 54% (2640) were female, mean age was 33 years (standard deviation 11) and 84% (4092) had partners living with HIV. PrEP continuation was 57%, 44%, and 34% at 1, 3, and 6 months, respectively. Four unique trajectories of PrEP coverage were identified: (1) one-fourth (1154) exhibited consistent high coverage throughout the year with 93%, 94%, 96%, and 67% continuing PrEP at months 1, 3, 6, and 12, respectively; (2) 13% (682) showed high coverage trajectory throughout 6 months but coverage rapidly declined thereafter (94%, 93%, 63%, and 10% continued at months 1, 3, 6, and 12, respectively); (3) 18.9% (918) exhibited moderate coverage trajectory with 91% of clients refilling PrEP at month 1 but nearly all dropped-off thereafter (37%, 5%, and 4% continued at months 3, 6, and 12, respectively); and (4) 43.8% (2144) exhibited immediate discontinuation trajectory, in which nearly all did not have any subsequent PrEP refill. Overall, being female, older age, having partners living with HIV or of unknown HIV status were statistically associated with better PrEP continuation trajectories compared to the immediate discontinuation trajectory (p <0.05 for all).

conclusionsIn this analysis of a real-world PrEP implementation programme in Kenya, we found four distinct patterns of PrEP continuation, with one-third of users exhibiting consistent high continuation throughout 12 months and two-fifths with immediate discontinuation patterns. These data may help guide tailored interventions to support PrEP continuation in this setting.

Indexed as

Anti-HIV AgentsHIV InfectionsPre-Exposure ProphylaxisAdultFemaleHumansKenyaLatent Class AnalysisMaleAnti-HIV AgentsadherenceHIV preventionKenyaPrEPretentionrisk factors

Identifiers

PMID37403405
PMCPMC10320042
OpenAlexW4383186793

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.